Skip to main content
TipRanks
Go Ultimate75% OFF

China Regenerative Medicine International Limited (8158) Stock Price & Analysis

0 Followers

8158 Stock Chart & Stats

HK$0.24-HK$0.00(-0.42%)
At close: 4:00 PM GMT+8
HK$0.2HK$0.25HK$0.3Aug 24Sep 7Sep 21Oct 6Oct 20Nov 3Nov 17
Day’s Range
HKD 0.24 - HKD 0.24
52-Week Range
HKD 0.06 - HKD 0.66
Previous Close
HKD 0.24
Volume
N/A
Average Volume (3M)
13.40K
Market Cap
HKD 71.80M
Enterprise Value
HKD 130.75M
Total Cash (Recent Filing)
HKD 1.82M
Total Debt (Recent Filing)
HKD 38.25M
Price to Earnings (P/E)
2.4
Beta
-0.47
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profitability

Strong TTM revenue growth combined with healthy gross and net margins indicates meaningful commercial traction and current earnings capacity. If maintained, this combination can strengthen internal funding, support continued investment in healthcare activities, and improve resilience over the next several quarters.

Deleveraging

The substantial reduction in leverage materially improves financial flexibility compared with the stressed 2023–2024 period. A stronger equity base and lower debt burden can reduce balance-sheet pressure, improve funding resilience, and give management more room to allocate capital toward operations.

Improved Cash Generation

The sharp improvement in operating and free cash flow is a constructive sign that recent reported profitability is translating into cash. Free cash flow broadly matching profit supports earnings durability and gives the company greater capacity to fund needs without relying as heavily on external financing.

Bears Say

Revenue Volatility

Large year-to-year revenue swings make the current growth rate harder to treat as a stable trend. Volatile demand or business performance can reduce forecasting confidence, complicate resource planning, and make future margins and earnings less dependable even when the latest TTM results are strong.

Inconsistent Cash Conversion

Although TTM cash generation has improved, the historical pattern of negative or weak operating cash flow shows that accounting profit has not consistently converted into cash. Recurring conversion weakness could constrain self-funded growth and create greater dependence on balance-sheet resources during softer periods.

Earnings Quality Risk

Profitability alongside negative EBIT raises questions about the consistency and operating quality of earnings, while sharp asset and equity movements point to an unstable financial base. These factors make it harder to assess recurring operating power and increase the risk that recent results may not persist.

8158 FAQ

What was China Regenerative Medicine International Limited’s price range in the past 12 months?
China Regenerative Medicine International Limited lowest stock price was HK$0.06 and its highest was HK$0.66 in the past 12 months.
What is China Regenerative Medicine International Limited’s market cap?
China Regenerative Medicine International Limited’s market cap is HK$71.80M.
When is China Regenerative Medicine International Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Regenerative Medicine International Limited’s earnings last quarter?
China Regenerative Medicine International Limited released its earnings results on Aug 21, 2026. The company reported HK$0.015 earnings per share for the quarter.
Is China Regenerative Medicine International Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does China Regenerative Medicine International Limited pay dividends?
China Regenerative Medicine International Limited does not currently pay dividends.
What is China Regenerative Medicine International Limited’s EPS estimate?
China Regenerative Medicine International Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Regenerative Medicine International Limited have?
China Regenerative Medicine International Limited has 304,252,470 shares outstanding.
What happened to China Regenerative Medicine International Limited’s price movement after its last earnings report?
China Regenerative Medicine International Limited reported an EPS of HK$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of China Regenerative Medicine International Limited?
Currently, no hedge funds are holding shares in HK:8158
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology